Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
2019 ◽
Vol 20
(1)
◽
pp. 43-56
◽
Keyword(s):
Phase 3
◽